Gastrointestinal Stromal Tumor Market Report and Growth
Introduction:
The Global Gastrointestinal Stromal Tumor (GIST) Market is witnessing significant growth, driven by the increasing prevalence of gastrointestinal cancers, rising awareness regarding early diagnosis, and continuous advancements in targeted cancer therapies. Gastrointestinal stromal tumors are rare mesenchymal tumors that require specialized treatment approaches, including targeted therapies and precision medicine. Growing investments in oncology research, expanding clinical trials, and increasing adoption of personalized treatment strategies are expected to support long-term market growth globally.
Get Free Sample Of This Premium Report:
https://www.decisionsadvisors.com/request-sample/DAR4476
Gastrointestinal Stromal Tumor Market Insights
Based on Deep Market Insights findings, the Global Gastrointestinal Stromal Tumor Market was valued at USD 874.0 Million in 2024 and is estimated to attain USD 2,499.1 Million by 2035.
From 2025 to 2035, the market is expected to grow at a CAGR of 10.02%.
Within the Treatment Type category, Targeted Therapy dominated in 2024 in terms of market size contribution.
Over the forecast period, Tyrosine Kinase Inhibitors (TKIs) and Precision Oncology Therapies are forecasted to deliver the fastest growth due to increasing clinical efficacy, improved survival outcomes, and expanding adoption of personalized cancer treatment approaches.
Other Key Findings
• North America accounted for a significant share of the global Gastrointestinal Stromal Tumor Market in 2024 and remained a major revenue-generating region.
• Asia-Pacific is expected to emerge as the fastest-growing regional market owing to improving healthcare infrastructure, increasing cancer awareness, rising healthcare expenditure, and expanding access to advanced oncology therapies.
• Europe remained a key regional market supported by strong oncology research, favorable reimbursement policies, and growing adoption of targeted therapies.
• Continuous advancements in molecular diagnostics, precision medicine, and targeted drug development continue to support global market growth.
Report Summary
Report Scope
Details
|
Parameter |
Information |
|
Base Year for Study |
2024 |
|
Study Period |
2021–2035 |
|
Historical Period |
2021–2024 |
|
Forecast Period |
2025–2035 |
|
Market Size In 2024 |
USD 874.0 Million |
|
Market Size In 2035 |
USD 2,499.1 Million |
|
Fastest Growing Region |
Asia-Pacific |
|
Units |
Revenue in USD Million |
|
CAGR |
10.02% (2025–2035) |
Segmentation Covered
|
Category |
Segments |
|
Treatment Type |
1. Targeted Therapy 2. Chemotherapy 3. Surgery 4. Radiation Therapy 5. Others |
|
Drug Class |
1. Imatinib 2. Sunitinib 3. Regorafenib 4. Ripretinib 5. Avapritinib 6. Others |
|
End User |
1. Hospitals 2. Specialty Cancer Centers 3. Ambulatory Surgical Centers 4. Research Institutes |
|
Distribution Channel |
1. Hospital Pharmacies 2. Retail Pharmacies 3. Online Pharmacies |
|
Region |
1. North America 2. Europe 3. Asia-Pacific 4. Latin America 5. Middle East & Africa |
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Drivers, Industry Trends, Technology Advancements, Regulatory Landscape, Clinical Research Analysis, Treatment Pipeline Assessment, and Regional Analysis.
Companies
Novartis AG, Bayer AG, Pfizer Inc., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd., Deciphera Pharmaceuticals, Blueprint Medicines Corporation, Eli Lilly and Company, Johnson & Johnson, and AstraZeneca PLC.
Want detailed insights, forecasts, and competitive analysis?
Check out the full report now:
https://www.decisionsadvisors.com/reports/gastrointestinal-stromal-tumor-market
Connect with us
- USA - +1 303 800 4326
- APAC - +1 303 800 4326
- sales@sphericalinsights.com